Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    fkd
Show Display Options
Rank Status Study
1 Not yet recruiting Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients
Condition: Venous Leg Ulcer
Intervention: Device: geko plus R-2
2 Recruiting Midds Ankle Fracture
Condition: Ankle Fracture Requiring Internal Fixation
Intervention: Device: geko neuromuscular electrostimulation device
3 Withdrawn IPC-CALF Versus GEKO in Post-op Total Hip Patients
Condition: Total Hip Replacement
Interventions: Device: geko;   Device: IPC-Calf
4 Recruiting Feasibility Study of the Use of the gekoTM Device for Faecal Incontinence in Older People Living at Home or in Care Homes
Condition: Fecal Incontinence
Intervention: Device: geko(TM) device
5 Completed Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema
Conditions: Oedema;   Neuropathy
Intervention: Device: electrical stimulation
6 Recruiting Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study
Condition: Deep Vein Thrombosis
Interventions: Device: geko™ post-surgery for 48hrs then 4hrs/day until discharge.;   Device: TEDS post-surgery for 48hrs then 4hrs/day until discharge.
7 Completed Firefly ANKLE Sprain Study
Condition: Grade I/II Ankle Sprain
Interventions: Device: firefly;   Other: Standard of care
8 Recruiting A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC
Condition: Superficial Bladder Cancer
Intervention: Biological: INSTILADRIN
9 Completed Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
Condition: Superficial Bladder Cancer
Intervention: Drug: INSTILADRIN
10 Active, not recruiting 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: SCH 721015

Indicates status has not been verified in more than two years